In a study investigating the response of IGF-I levels to GH replacement therapy in pediatric patients with CLD [42], it was reported that hepatic GH resistance is identified early in the disease process and becomes more pronounced as the disease progresses, especially in association with portal hypertension. The gene discussed is GH1; the disease is portal hypertension.